Tesamorelin (Egrifta) Explained: An FDA-Approved GHRH Analog for HIV Lipodystrophy
Tesamorelin has one thing no other GHRH analog peptide can claim: an FDA approval. That approval is real, the Phase 3 trial data behind it are solid, and the mechanism is well understood. But the indication is narrow — HIV-associated lipodystrophy, specifically the excess visceral fat that accumulates in people on long-term antiretroviral therapy — […]
Tesamorelin (Egrifta) Explained: An FDA-Approved GHRH Analog for HIV Lipodystrophy Read More »









